Literature DB >> 20532549

Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary.

Adebukola Adebayo1, Jignesh G Parikh, Steven A McCormick, Mahendra K Shah, Remedios S Huerto, Guopei Yu, Tatyana Milman.   

Abstract

BACKGROUND: Bacterial conjunctivitis is one of the most common forms of ocular diseases worldwide. The purpose of this study is to determine the most common pathogens causing bacterial conjunctivitis, their in vitro susceptibility to existing antibiotics, and the changing trends in bacterial resistance to antibiotics over the last decade.
METHODS: Records of all conjunctival bacterial cultures performed at the NYEEI Microbiology Laboratory from 1 January 1997 through 30 June 2008 were reviewed. Data on species of bacterial isolates and their in vitro susceptibility to the antibiotics tetracycline, trimethaprim/sulfamethoxazole (TMP/SMZ), imipenem, fluoroquinolones (ciprofloxacin, moxifloxacin, gatifloxacin), aminoglycosides (gentamicin, tobramycin), erythromycin, cefazolin, oxacillin, and vancomycin were collected.
RESULTS: Review of records yielded 20,180 conjunctival bacterial cultures, 60.1% of which were culture-positive. Of the culture-positive isolates, 76.6% were gram-positive and 23.4% were gram-negative pathogens. Staphylococcus aureus was the most common gram-positive pathogen isolated, and also the most commonly isolated pathogen overall. Haemophilus influenzae was the most common gram-negative pathogen. A significant increase in the percentage of methicillin-resistant Staphylococcus aureus (MRSA) was observed in the course of 11.5 years. The highest levels of antibiotic resistance were observed to tetracycline, erythromycin, and TMP/SMZ. Gram-positive isolates were least resistant to vancomycin, and gram-negative isolates were least resistant to imipenem. The lowest broad-spectrum antibiotic resistance was observed in the case of moxifloxacin, gatifloxacin, and aminoglycosides.
CONCLUSION: Staphylococcus aureus is the most common pathogen in bacterial conjunctivitis. Conjunctival bacterial isolates demonstrated high levels of resistance to tetracycline, erythromycin and TMP/SMZ. Moxifloxacin and gatifloxacin appear to be currently the best choice for empirical broad-spectrum coverage. Vancomycin is the best antibiotic for MRSA coverage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20532549     DOI: 10.1007/s00417-010-1426-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  Intracameral cefazolin to prevent endophthalmitis in cataract surgery: 3-year retrospective study.

Authors:  Magela Garat; Carlos L Moser; Carlos Alonso-Tarrés; Montserrat Martín-Baranera; Aintzane Alberdi
Journal:  J Cataract Refract Surg       Date:  2005-11       Impact factor: 3.351

Review 2.  Bacterial conjunctivitis: a review for internists.

Authors:  Ahmad B Tarabishy; Bennie H Jeng
Journal:  Cleve Clin J Med       Date:  2008-07       Impact factor: 2.321

3.  How do general practitioners manage eye disease in the community?

Authors:  P J McDonnell
Journal:  Br J Ophthalmol       Date:  1988-10       Impact factor: 4.638

4.  Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998).

Authors:  S L Block; J Hedrick; R Tyler; A Smith; R Findlay; E Keegan; D W Stroman
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.

Authors:  G Alexandrakis; E C Alfonso; D Miller
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079

Review 6.  The evolution of antibiotic therapy for bacterial conjunctivitis and keratitis: 1970-2000.

Authors:  J Baum; M Barza
Journal:  Cornea       Date:  2000-09       Impact factor: 2.651

7.  Major age group-specific differences in conjunctival bacteria and evolution of antimicrobial resistance revealed by laboratory data surveillance.

Authors:  Nina Hautala; Markku Koskela; Timo Hautala
Journal:  Curr Eye Res       Date:  2008-11       Impact factor: 2.424

8.  Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.

Authors:  Penny A Asbell; Daniel F Sahm; Mary Shaw; Deborah C Draghi; Nina P Brown
Journal:  J Cataract Refract Surg       Date:  2008-05       Impact factor: 3.351

9.  Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus.

Authors:  Julie Freidlin; Nisha Acharya; Thomas M Lietman; Vicky Cevallos; John P Whitcher; Todd P Margolis
Journal:  Am J Ophthalmol       Date:  2007-08       Impact factor: 5.258

Review 10.  Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.

Authors:  George Sakoulas; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

View more
  24 in total

1.  Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.

Authors:  Jesse DeLeon; Bruce E Silverstein; Catherine Allaire; Lynne S Gearinger; Kirk M Bateman; Timothy W Morris; Timothy L Comstock
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

2.  Conjunctivitis: systematic approach to diagnosis and therapy.

Authors:  Onsiri Thanathanee; Terrence P O'Brien
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

Review 3.  Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

4.  Epidemiology and Outcome of Microbial Keratitis: Private University Versus Urban Public Hospital Care.

Authors:  David T Truong; Minh-Thuy Bui; H Dwight Cavanagh
Journal:  Eye Contact Lens       Date:  2018-09       Impact factor: 2.018

5.  Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.

Authors:  Bruce E Silverstein; Timothy W Morris; Lynne S Gearinger; Heleen H Decory; Timothy L Comstock
Journal:  Clin Ophthalmol       Date:  2012-11-30

6.  Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.

Authors:  Lorenzo J Cervantes; Francis S Mah
Journal:  Clin Ophthalmol       Date:  2011-04-18

7.  Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.

Authors:  Wolfgang Haas; Lynne S Gearinger; Dale W Usner; Heleen H Decory; Timothy W Morris
Journal:  Clin Ophthalmol       Date:  2011-09-21

8.  Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study.

Authors:  Ranjan Malhotra; Joseph Gira; Gregg J Berdy; Robert Brusatti
Journal:  Clin Ophthalmol       Date:  2012-06-05

9.  Staphylococcus aureus ocular infection: methicillin-resistance, clinical features, and antibiotic susceptibilities.

Authors:  Chih-Chun Chuang; Ching-Hsi Hsiao; Hsin-Yuan Tan; David Hui-Kang Ma; Ken-Kuo Lin; Chee-Jen Chang; Yhu-Chering Huang
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

Review 10.  A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States.

Authors:  Paulo J M Bispo; Daniel F Sahm; Penny A Asbell
Journal:  Ophthalmol Ther       Date:  2022-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.